• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Regenetech, Johns Hopkins University Collaborate for Diabetes Treatment

Posted on: Thursday, 15 November 2007, 12:00 CST

Regenetech has signed a sponsored research agreement with Johns Hopkins University for a type I diabetes treatment.

Regenetech's agreement with Johns Hopkins University will span over two years, and involves significant funding from the company. The goal of the research project is to develop a treatment for type I diabetes using a patient's own adult stem cells expanded in Regenetech's Intrifuge Bioreactor system.

The company has signed a sub-license agreement with University of Texas Medical Branch at Galveston, to use Regenetech's NASA licensed Intrifuge Bioreactor system to expand the stem cells found in the blood. The ultimate goal is to provide low cost, safe doses of adult stem cells for a broad range of diseases and known therapies.

Regenetech also has a sponsored research agreement with Texas A&M University for the treatment of bone fractures in animals. The research is to demonstrate the clinical efficacy of NASA's patented time-varying electromagnetic field technology, which is exclusively licensed to Regenetech.

David Bonner, CEO of Regenetech, said: "Any new intellectual property that is generated from these research agreements will be owned by the respective universities, but we have the right to negotiate exclusive licenses. The agreement with Johns Hopkins University has potentially significant implications for the treatment of type I diabetes, and we look forward to announcing the results of our collaboration with them."

Source: Datamonitor

More News in this Category